Hannah Naughton, MD, explains how de-escalating surgery and chemotherapy in breast cancer expands breast conservation and ...
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy. The oral EGFR inhibitor sunvozertinib (Zegfrovy) is ...
These developments also strengthen the rationale for next-generation sequencing (NGS) in patients with early-stage disease.
The investigational folate receptor alpha (FRα)–targeted antibody-drug conjugate (ADC) sofetabart mipitecan (LY4170156) ...
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining ...
Matthew Gubens, MD, MS, explains how targeted therapies are moving into earlier-stage non–small cell lung cancer, while ...
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic ...
New analysis reveals major gaps in US TNBC trial access, leaving rural and minority communities with fewer treatment options ...
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET ...
Rusfertide (Mimrylo) significantly improved hematocrit control and reduced the need for therapeutic phlebotomy in patients ...
The FDA has granted accelerated approval to dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal ...
The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results